Clinical trial

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg…

NCT00305448 · AstraZeneca, Industry · Completed

Key facts

NCT number NCT00305448
Title A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
Official title Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
Acronym FINDER I
Lead sponsor AstraZeneca, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Advanced Breast Cancer, Metastatic Breast Cancer
Intervention type Drug
Interventions Fulvestrant
Enrollment 143
Start date Mar 1, 2006
Primary completion Mar 1, 2008
Completion Feb 1, 2012
First posted Mar 22, 2006
Last update posted Feb 15, 2012
Countries Japan

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies